Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intranasal, Intramuscular, and Oral Naltrexone
NCT02750748Phase 1Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naltrexone in opioid use disorder (OUD), sponsored by National Institute on Drug Abuse. Primary endpoint: Plasma Concentration (Cmax) at 48 hours. Started Jul 2016; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02750748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750748.